Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 4/20 | 0.48 |
| ▸ | TLR1 | Q15399 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4635443 | 0.83 | TLR2 (0.48) | TLR2TLR1NPC1RAB9AATM | |
| SCHEMBL4635445 | 0.76 | TLR2 (0.47) | TLR2TLR1NPC1RAB9AATM | |
| SCHEMBL4635408 | 0.76 | MITF (0.54) | NPC1RAB9AATMKMT2AMEN1 | |
| SCHEMBL4898863 | 0.73 | DPP4 (0.55) | — | |
| SCHEMBL4635067 | 0.71 | HSD11B1 (0.51) | TLR2TLR1NPC1RAB9AATM | |
| SCHEMBL27777255 | 0.70 | HSD11B1 (0.57) | TLR2TLR1NPC1RAB9AATM | |
| SCHEMBL4669126 | 0.69 | DPP4 (0.45) | TLR2TLR1NPC1RAB9AATM | |
| SCHEMBL30937118 | 0.69 | HSD11B1 (0.56) | TLR2TLR1NPC1RAB9AATM | |
| SCHEMBL26255947 | 0.68 | PAX8 (0.57) | TLR2TLR1NPC1RAB9AATM | |
| SCHEMBL15973607 | 0.67 | MAPT (0.58) | NPC1RAB9AKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| EP-1931633-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007029086-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP8 | TLR2 3383/4885TLR1 3085/4885NPC1 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.